Drug Target Review

NOVEMBER 6, 2023

To bring us closer to curing cancer, a combination of effective drugs with non-overlapping mechanisms of action is required. 6 In all these examples, an effective backbone drug was first developed, before adding one or more drugs to establish the new regimens. 2012);12(4):237-251. Front Pharmacol. 2018;9:1300.

Small Molecule 111

Small Molecule Therapies Treatment Disease 111

Drug Target Review

NOVEMBER 1, 2023

I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. The mission of the CCDD is to discover novel small-molecule therapeutics for the treatment of cancer and progress them to hypothesis testing phase 1 clinical trials.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

NIH Director's Blog: Drug Development

JULY 20, 2017

These results, along with data from another clinical trial expected to begin later this year, will be used by Vertex to select which next-generation targeted drug or combination of drugs will move forward into larger scale Phase III studies. About 30,000 Americans have CF.

Clinical Trials 52

Clinical Trials Small Molecule Therapies Disease 52

NIH Director's Blog: Drug Development

APRIL 7, 2015

After a whirlwind tour of the cutting-edge robotics facility for high throughput screening of small molecules, she joined me and NCATS Director Dr. Chris Austin in announcing that, thanks to an innovative public-private partnership, an experimental drug originally developed to fight cancer is now showing promise against Alzheimer’s disease.

Disease 40

Disease Drugs Clinical Trials Science 40

New Drug Approvals

SEPTEMBER 13, 2024

“LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders” Neuropharmacology. Rankovic Z, Hargreaves R, Bingham M (2012). Drug Discovery for Psychiatric Disorders. Drug Discovery.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Agency IQ

APRIL 19, 2024

Although therapeutics have contributed to improvements in survival, the five-year relative survival rate for patients with MM was just 57% between 2012 and 2018. Note: Both analyses focused only on studies of small molecules, antibodies and biologics; studies of CAR T therapies were not included.

FDA 40

FDA Disease Trials Clinical Trials 40

The Pharma Data

DECEMBER 27, 2020

BRUKINSA (zanubrutinib) is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), discovered by BeiGene scientists, that is currently being evaluated globally in a broad pivotal clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies. 2012 Aug 2;120(5):947-59.

Production 52

Production Therapies Treatment Drugs 52